News Release

Low-dose atropine eye drops vs placebo for myopia control

JAMA Ophthalmology

Peer-Reviewed Publication

JAMA Network

About The Study: In this randomized clinical trial of school-age children in the U.S. with low to moderate myopia (nearsightedness), atropine, 0.01%, eye drops administered nightly when compared with placebo did not slow myopia progression or axial elongation. These results do not support use of atropine, 0.01%, eye drops to slow myopia progression or axial elongation in U.S. children.

Authors: Michael X. Repka, M.D., M.B.A., of the Wilmer Eye Institute in Baltimore, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link 


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.